PL2061810T3 - Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał - Google Patents

Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał

Info

Publication number: PL2061810T3
Authority: PL; Poland
Prior art keywords: compositions; treatment; methods; antibody mediated; mediated neuropathies
Prior art date: 2006-09-05

Application number

PL07837788T

Other languages

English (en)

Inventor

Susan Halstead

Hugh Willison

Russell P Rother

Original Assignee

Alexion Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-05

Filing date

2007-09-05

Publication date

2015-05-29

2007-09-05 Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc

2015-05-29 Publication of PL2061810T3 publication Critical patent/PL2061810T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Biotechnology (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL07837788T 2006-09-05 2007-09-05 Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał PL2061810T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US84229606P	2006-09-05	2006-09-05
EP07837788.4A EP2061810B1 (en)	2006-09-05	2007-09-05	Methods and compositions for the treatment of antibody mediated neuropathies
PCT/US2007/019416 WO2008030505A2 (en)	2006-09-05	2007-09-05	Methods and compositions for the treatment of antibody mediated neuropathies

Publications (1)

Publication Number	Publication Date
PL2061810T3 true PL2061810T3 (pl)	2015-05-29

Family

ID=39157834

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07837788T PL2061810T3 (pl)	2006-09-05	2007-09-05	Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał

Country Status (16)

Country	Link
US (1)	US9388235B2 (pl)
EP (4)	EP2380907B1 (pl)
JP (2)	JP5695317B2 (pl)
KR (1)	KR101503540B1 (pl)
AU (1)	AU2007293013B2 (pl)
BR (1)	BRPI0715869A2 (pl)
CA (1)	CA2662480C (pl)
DK (1)	DK2061810T3 (pl)
ES (2)	ES2616204T3 (pl)
IL (1)	IL197148A (pl)
MX (1)	MX2009002426A (pl)
NZ (1)	NZ575018A (pl)
PL (1)	PL2061810T3 (pl)
PT (1)	PT2061810E (pl)
SI (1)	SI2061810T1 (pl)
WO (1)	WO2008030505A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2359834T5 (en)	2006-03-15	2017-02-06	Alexion Pharma Inc	Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
GB0617734D0 (en)	2006-09-08	2006-10-18	Evolutec Ltd	Method of treating peripheral nerve disorders
CN102203604B (zh) *	2008-10-21	2014-09-10	托马斯·M·东德林格	用于防止组织样品中伪像的方法和组合物
WO2013126006A1 (en)	2012-02-20	2013-08-29	Swedish Orphan Biovitrum Ab (Publ)	Polypeptides binding to human complement c5
EP2912065A4 (en)	2012-10-25	2016-10-19	True North Therapeutics Inc	ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
RS63212B1 (sr)	2012-11-02	2022-06-30	Bioverativ Usa Inc	Antikomplementna c1s antitela i njihove primene
EP2996722A4 (en) *	2013-05-15	2017-01-11	Annexon, Inc.	Methods of treatment for guillain-barre syndrome
KR102321320B1 (ko)	2013-07-09	2021-11-03	애넥슨, 인코포레이티드	항-보체 인자 ｃ１ｑ 항체 및 이의 용도
KR20160132034A (ko)	2014-03-13	2016-11-16	우니페르시테트 바젤	미엘린-관련 당단백질에 대한 IgM 항체와 결합하는 탄수화물 리간드
US10316081B2 (en)	2014-11-05	2019-06-11	Annexon, Inc.	Humanized anti-complement factor C1Q antibodies
WO2016097865A1 (en) *	2014-12-19	2016-06-23	Regenesance B.V.	Antibodies that bind human c6 and uses thereof
BR112017021289A2 (en)	2015-04-06	2018-06-26	Bioverativ Usa Inc.	humanized anti-c1s antibodies and methods of use
HK1252262A1 (zh)	2015-09-16	2019-05-24	巴塞尔大学	结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
BR112018010360A2 (en)	2015-11-24	2018-12-04	Annexon, Inc.	anti-c1q complement factor fab fragments and uses thereof
MY191668A (en)	2016-06-14	2022-07-06	Regeneron Pharma	Anti-c5 antibodies and uses thereof
EP3525583B8 (en)	2016-10-12	2025-09-10	Bioverativ USA Inc.	Anti-c1s antibodies and methods of use thereof
JP2021506241A (ja)	2017-12-13	2021-02-22	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	抗ｃ５抗体組み合わせ物およびその使用
US20190247560A1 (en)	2018-02-13	2019-08-15	Gambro Lundia Ab	Extracorporeal devices and methods of treating complement factor related diseases
SG11202103972SA (en) *	2018-10-22	2021-05-28	Ra Pharmaceuticals Inc	Neurological disease treatment with zilucoplan
GB2584105B (en) *	2019-05-21	2023-08-02	Argenx Bvba	Methods of treating neuropathy
US12486322B2 (en)	2021-12-13	2025-12-02	Annexon, Inc.	Anti-complement factor C1q antibodies with single binding arms and uses thereof
TW202404632A (zh) *	2022-04-04	2024-02-01	瑞士商赫孚孟拉羅股份公司	用於藉由使用抗ｃ５抗體克羅伐單抗治療或預防格林－巴利症候群之劑量及投予方案

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5705732A (en)	1989-06-12	1998-01-06	Oklahoma Medical Research Foundation	Universal donor cells
US5135916A (en)	1989-06-12	1992-08-04	Oklahoma Medical Research Foundation	Inhibition of complement mediated inflammatory response
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0560929A1 (en)	1990-12-06	1993-09-22	T Cell Sciences, Inc.	Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US6027725A (en)	1991-11-25	2000-02-22	Enzon, Inc.	Multivalent antigen-binding proteins
AU3178993A (en)	1991-11-25	1993-06-28	Enzon, Inc.	Multivalent antigen-binding proteins
US5456909A (en)	1992-08-07	1995-10-10	T Cell Sciences, Inc.	Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
DK1231268T3 (da)	1994-01-31	2005-11-21	Univ Boston	Polyklonale antistofbiblioteker
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
EP0777474B1 (en)	1994-09-23	2005-12-21	Alexion Pharmaceuticals, Inc.	Methods for the treatment of inflammatory joint disease
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
US6991790B1 (en)	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
WO1999037149A1 (en) *	1998-01-27	1999-07-29	Brigham & Women's Hospital	Methods of treating cytotoxic damage
WO2000047194A2 (en) *	1999-02-09	2000-08-17	3-Dimensional Pharmaceuticals, Inc.	METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
AU2001296594A1 (en)	2000-10-10	2002-04-22	Tanox, Inc.	Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7432356B2 (en)	2001-08-17	2008-10-07	Genentech, Inc.	Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
ITMI20021527A1 (it) *	2002-07-11	2004-01-12	Consiglio Nazionale Ricerche	Anticorpi anti componente c5 del complemento e loro uso
SI1523496T1 (sl)	2002-07-18	2011-11-30	Merus B V	Rekombinantno proizvajanje zmesi protiteles
AU2003265361A1 (en)	2002-08-28	2004-03-19	Pharmacia Corporation	Stable ph optimized formulation of a modified antibody
CA2512174A1 (en)	2003-01-30	2004-08-12	Christian B. Allan	Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof
DK1610820T4 (da)	2003-04-04	2013-11-04	Genentech Inc	Høj-koncentration antistof- og proteinformuleringer
WO2005002513A2 (en) *	2003-06-16	2005-01-13	The Brigham And Women's Hospital, Inc.	C1q complement inhibitors and methods of use thereof
US7482376B2 (en)	2003-07-03	2009-01-27	3-Dimensional Pharmaceuticals, Inc.	Conjugated complement cascade inhibitors
EP1739078A1 (de) *	2005-05-30	2007-01-03	Jerini AG	C5a-Rezeptor-Antagonisten
EP1988882B1 (en)	2006-03-02	2014-12-17	Alexion Pharmaceuticals, Inc.	Prolongation of survival of an allograft by inhibiting complement activity

2007
- 2007-09-05 EP EP11005615.7A patent/EP2380907B1/en active Active
- 2007-09-05 EP EP16201244.7A patent/EP3199549A1/en not_active Withdrawn
- 2007-09-05 BR BRPI0715869-6A2A patent/BRPI0715869A2/pt not_active Application Discontinuation
- 2007-09-05 NZ NZ575018A patent/NZ575018A/en not_active IP Right Cessation
- 2007-09-05 EP EP07837788.4A patent/EP2061810B1/en active Active
- 2007-09-05 DK DK07837788.4T patent/DK2061810T3/en active
- 2007-09-05 KR KR1020097004369A patent/KR101503540B1/ko active Active
- 2007-09-05 ES ES11005615.7T patent/ES2616204T3/es active Active
- 2007-09-05 US US12/439,070 patent/US9388235B2/en active Active
- 2007-09-05 EP EP14192554.5A patent/EP2913342A1/en not_active Withdrawn
- 2007-09-05 SI SI200731601T patent/SI2061810T1/sl unknown
- 2007-09-05 ES ES07837788T patent/ES2530428T3/es active Active
- 2007-09-05 WO PCT/US2007/019416 patent/WO2008030505A2/en not_active Ceased
- 2007-09-05 AU AU2007293013A patent/AU2007293013B2/en active Active
- 2007-09-05 PL PL07837788T patent/PL2061810T3/pl unknown
- 2007-09-05 JP JP2009527404A patent/JP5695317B2/ja not_active Expired - Fee Related
- 2007-09-05 MX MX2009002426A patent/MX2009002426A/es active IP Right Grant
- 2007-09-05 CA CA2662480A patent/CA2662480C/en active Active
- 2007-09-05 PT PT78377884T patent/PT2061810E/pt unknown
2009
- 2009-02-19 IL IL197148A patent/IL197148A/en active IP Right Grant
2014
- 2014-09-26 JP JP2014196133A patent/JP2014240438A/ja active Pending

Also Published As

Publication number	Publication date
EP2380907B1 (en)	2016-11-30
EP2913342A1 (en)	2015-09-02
NZ575018A (en)	2012-04-27
MX2009002426A (es)	2009-03-20
EP3199549A1 (en)	2017-08-02
WO2008030505A2 (en)	2008-03-13
JP2014240438A (ja)	2014-12-25
ES2616204T3 (es)	2017-06-09
JP5695317B2 (ja)	2015-04-01
EP2061810B1 (en)	2014-11-12
IL197148A0 (en)	2011-08-01
EP2061810A2 (en)	2009-05-27
PT2061810E (pt)	2015-02-05
DK2061810T3 (en)	2015-02-16
IL197148A (en)	2016-06-30
AU2007293013A1 (en)	2008-03-13
JP2010502708A (ja)	2010-01-28
AU2007293013B2 (en)	2013-06-27
WO2008030505A3 (en)	2008-06-19
EP2380907A1 (en)	2011-10-26
KR101503540B1 (ko)	2015-03-17
HK1126793A1 (en)	2009-09-11
CA2662480C (en)	2016-11-08
US9388235B2 (en)	2016-07-12
KR20090051063A (ko)	2009-05-20
BRPI0715869A2 (pt)	2013-07-30
CA2662480A1 (en)	2008-03-13
SI2061810T1 (sl)	2015-04-30
US20100143343A1 (en)	2010-06-10
ES2530428T3 (es)	2015-03-02
WO2008030505A8 (en)	2009-03-05

Publication	Publication Date	Title
IL197148A0 (en)	2011-08-01	Methods and compositions for the treatment of antibody mediated neuropathies
SI2079760T1 (sl)	2016-11-30	Sestavki in metode za zdravljenje okužb
PT2546253E (pt)	2015-05-07	Di-hidropirazolonas substituídas para o tratamento de doenças cardiovasculares e hematológicas
IL197804A0 (en)	2009-12-24	Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c
IL196465A0 (en)	2009-11-18	Compositions and methods for the treatment of mucositis
IL181896A0 (en)	2007-07-04	Methods and compositions for the treatment of hyperlipidemia
IL193936A0 (en)	2009-08-03	Compositions and methods for the treatment of immunoinflammatory disorders
EP2049151A4 (en)	2010-03-24	METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2007385A4 (en)	2010-08-18	CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
PT2340042E (pt)	2014-11-27	Métodos e composições para o tratamento de cancro
AU2007243282A8 (en)	2008-11-27	Compositions and methods for the treatment of cardiovascular disease
IL195272A0 (en)	2009-08-03	Methods and compositions for the treatment of viral infections
EP2331123A4 (en)	2012-11-07	COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C
IL196843A0 (en)	2009-11-18	Compositions and methods for the treatment of radiation proctosigmoitis
GB0718446D0 (en)	2007-10-31	Compositions and methods for the treatment of infection
IL198723A0 (en)	2010-02-17	Methods and compositions for therapeutic treatment
EP1996218A4 (en)	2012-07-11	METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
IL189009A0 (en)	2008-11-03	Methods and compositions for the treatment of neuropathies and related disorders
WO2007081751A9 (en)	2016-08-25	Compositions and methods for the treatment of cancer
IL196411A0 (en)	2011-08-01	Anti-cocaine compositions and treatment
ZA200703087B (en)	2009-04-29	Methods and compositions for the treatment of hyperlipidemia
EP2124968A4 (en)	2013-10-23	COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE ATROPHY
ZA200808600B (en)	2009-12-30	Methods and compositions for the detection and treatment of cancers
HUE026600T2 (hu)	2016-06-28	Készítmények és eljárások virális hepatitis kezelésére
GB0601950D0 (en)	2006-03-15	Compositions and methods of treating diabetes